These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28736830)

  • 1. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.
    Page MM; Watts GF
    Diabetes Obes Metab; 2018 Feb; 20(2):270-282. PubMed ID: 28736830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
    Hadjiphilippou S; Ray KK
    Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection.
    Pandey P; Zhao C; Liu B
    Methods Mol Biol; 2020; 2204():133-143. PubMed ID: 32710321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
    Scheen AJ; Wallemacq C; Lancellotti P
    Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
    Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.
    El Khoury P; Elbitar S; Ghaleb Y; Khalil YA; Varret M; Boileau C; Abifadel M
    Curr Atheroscler Rep; 2017 Oct; 19(12):49. PubMed ID: 29038906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
    Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
    Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.
    Karagiannis AD; Liu M; Toth PP; Zhao S; Agrawal DK; Libby P; Chatzizisis YS
    Curr Atheroscler Rep; 2018 Mar; 20(4):20. PubMed ID: 29525934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 targets important for lipid metabolism.
    Schulz R; Schlüter KD
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
    Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease.
    Delialis D; Dimopoulou MA; Papaioannou M; Kotsira G; Maneta E; Mavraganis G; Loutos C; Georgiopoulos G; Stamatelopoulos K
    Curr Pharm Des; 2023; 29(23):1802-1824. PubMed ID: 37055909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies.
    Ward NC; Page MM; Watts GF
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():52-62. PubMed ID: 31002454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.
    Milionis H; Liamis G; Elisaf M
    Expert Opin Biol Ther; 2015 Feb; 15(2):287-98. PubMed ID: 25491324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.